Table 1 Summary of the 14 randomized clinical trials included in the meta-analysis on the short-term effect of fenofibrate on CRP.
Index | Country | First author and publication year | Dose (mg/day) | Duration (weeks) | Sample size | Population | Randomized? |
|---|---|---|---|---|---|---|---|
1 | Korea | Kim et al., 2006 [40] | 200 | 8 | 54 | Patients with a triglyceride level > 200 mg/dL | Yes (Control group is general measures with low-calorie and low-fat diet and aerobic exercise) |
2 | UK | Fegan et al., 2005 [17] | 200 | 12 | 10 | Ambulatory male or female patients aged 40-75 years with Type 2 diabetes for more than 2 years | Yes (Compared with placebo) |
3 | Poland | Undas et al. 2005 [41] | 160 | 8 | 22 | Patients with LDL > 130 mg/dl and triglycerides < 300 mg/dl | Yes (Compared with Simvastatin) |
4 | Slovenia | Sebestjen et al., 2004 [42] | 250 | 12 | 38 | Healthy male volunteers, non-smokers, aged between 40 and 60 years, with combined hyperlipidemia | Yes (Compared with cerivastatin) |
5 | Taiwan | Wang et al.,2003 [43] | 200 | 8 | 35 | Triglyceride between 200 and 500 mg/dl, cholesterol > 200 mg/dl, and cholesterol/HDL ratio > 5 | Yes (Compared with Simvastatin) |
6 | Korea | Wi et al., 2010 [15] | 160 | 8 | 80 | Patients with triglyceride levels of 150-499 mg/dL, HDL levels < 45 mg/dL and LDL levels < 130 mg/dL | Yes (Compared with niacin) |
7 | Porland | Krysiak et al., 2010 [44] | 200 | 12 | 61 | Metabolic syndrome with pre-diabetes | Yes (Compared with placebo) |
8 | Porland | Krysiak et al., 2010 [44] | 200 | 12 | 19 | Metabolic syndrome without pre-diabetes | Yes (Compared with placebo) |
9 | USA-MI | Rosenson et al., 2010 [45] | 160 | 12 | 25 | Patients with the metabolic syndrome | Yes (Compared with placebo) |
10 | USA-TX | Belfort et al. 2010 [46] | 200 | 12 | 16 | Nondiabetic insulin-resistant MetS subjects | Yes (Compared with placebo) |
11 | Poland | Pruski et al., 2009 [24] | 267 | 8 | 30 | Type 2 diabetic patients with mixed dyslipidemia | Yes (Compared with placebo) |
12 | USA-UT | Muhlestein et al., 2006 [13] | 160 | 12 | 100 | Patients with type 2 diabetes, mixed dyslipidemia and no history of coronary heart disease | Yes (Compared with Simvastatin) |
13 | Poland | Okopien et al., 2006 [32] | 267 | 4 | 31 | Patients with impaired glucose tolerance | Yes (Compared with placebo) |
14 | Canada | Hogue et al., 2008 [18] | 200 | 6 | 19 | Type 2 diabetes mellitus subjects with hypertriglyceridemia | Yes (Compared with atorvastatin) |